Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA

(AZN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca plc : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 09:15am EDT

The company will report its earnings for FY 2018 on 02/14/2019. Generally, the company reports earnings better than estimates. In recent months, the 15 analysts from Thomson Reuters consensus have not revised their EPS estimates.

Annual earnings per share is expected at 1.93 USD for 2018 (- 18.4% from 2017). A summary of annual publications and estimates is available below.

Annual results2015201620172018 (e)2019 (e)
Sales
Million $
Released
Forecast
Spread
23 641
24 336
-2,9%
23 002
22 638
1,6%
22 465
21 834
2,9%

22 048

23 417
Operating income (EBITDA)
Million $
Released
Forecast
Spread
8 150
8 352
-2,4%
9 078
7 574
20%
9 891
8 207
21%

7 439

7 928
Operating profit (EBIT)
Million $
Released
Forecast
Spread
6 902
6 660
3,6%
6 721
6 455
4,1%
6 855
5 815
18%

5 819

6 276
Pre-Tax Profit (EBT)
Million $
Released
Forecast
Spread
3 069
3 146
-2,4%
3 406
2 344
45%
2 227
3 047
-27%

3 030

3 421
Net income
Million $
Released
Forecast
Spread
2 825
2 732
3,4%
3 499
2 519
39%
3 001
2 251
33%

2 495

2 793
EPS
 $
Released
Forecast
Spread
2,23
2,17
2,8%
2,77
2,18
27%
2,37
2,00
19%

1,93

2,16
Announcement Date02/04/201602/02/201702/02/2018
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA 1.71% 6919 Delayed Quote.15.84%
THOMSON REUTERS CORPORATION -0.34% 86.85 Delayed Quote.32.19%

© MarketScreener.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
10/22ASTRAZENECA : commits $35m to help young people tackle the threat of non-communi..
PU
10/21ASTRAZENECA : Farxiga Gets FDA OK to Reduce Hospitalization Risk in Type 2 Diabe..
DJ
10/21ASTRAZENECA : FARXIGA Approved in the US to Reduce the Risk of Hospitalization f..
BU
10/21ASTRAZENECA : U.S. FDA approves AstraZeneca diabetes drug for treating heart fai..
RE
10/21ASTRAZENECA : Farxiga approved in the US to reduce the risk of hospitalisation f..
PU
10/21ASTRAZENECA : Farxiga approved in the US to reduce the risk of
PU
10/21ASTRAZENECA : Farxiga approved in the US to reduce the risk of hospitalisationfo..
AQ
10/17ASTRAZENECA : Trastuzumab Deruxtecan Granted FDA Priority Review for Treatment o..
BU
10/17ASTRAZENECA : Trastuzumab deruxtecan granted FDA Priority Review for treatment o..
PU
10/17ASTRAZENECA : Trastuzumab deruxtecan granted FDA Priority Review
PU
More news
Financials (USD)
Sales 2019 23 935 M
EBIT 2019 6 455 M
Net income 2019 2 181 M
Debt 2019 11 418 M
Yield 2019 3,13%
P/E ratio 2019 52,8x
P/E ratio 2020 35,9x
EV / Sales2019 5,38x
EV / Sales2020 4,89x
Capitalization 117 B
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 95,91  $
Last Close Price 89,39  $
Spread / Highest target 45,1%
Spread / Average Target 7,28%
Spread / Lowest Target -24,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Marcus Wallenberg Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA15.84%115 597
JOHNSON & JOHNSON0.12%340 980
ROCHE HOLDING AG18.71%249 928
MERCK AND COMPANY6.40%208 158
PFIZER-16.54%201 496
NOVARTIS15.69%199 249